Optimizing Diagnosis and Management of NTM Lung Disease: A Case-based Podcast Series
Nontuberculous mycobacterial (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM, often occurring in patients with underlying lung diseases. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Understanding guidelines-based therapy for NTM will better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence. In this podcast series, faculty discuss 2 challenging cases of NTM lung disease and provide guidance on evidence-based management approaches.
Cost: FreeView Offer chevron_right
Free; 0.5 AMA PRA Category 1 Credit(s)™; The My Healio CME Dashboard keeps track of earned credits and saved activities; Personalized recommendations make finding your next activity easy; Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
Nontuberculous mycobacterial; NTM; Pulmonary disease; Lung disease
Upon successful completion of this educational activity, participants should be better able to: -Utilize available evidence-based guidelines to effectively manage NTM pulmonary disease. -Incorporate the latest clinical data in the selection of therapy for refractory NTM pulmonary disease.
The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with nontuberculous mycobacteria (NTM) infection.
Additional credit info
Provider Statement This continuing medical education activity is provided by Vindico Medical Education. Support Statement This activity is supported by an educational grant from Insmed Incorporated. Accreditation Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is approved for 1 year from the date of original release, November 17, 2020, to November 16, 2021.